|
This file is available on the Cryptome DVD offered by
Cryptome.
Cryptome DVD. Donate $25 for a DVD of the Cryptome 10-year archives of 35,000 files from June 1996 to June 2006 (~3.5 GB). Click Paypal or mail check/MO made out to John Young, 251 West 89th Street, New York, NY 10024. Archives include all files of cryptome.org, cryptome2.org, jya.com, cartome.org, eyeball-series.org and iraq-kill-maim.org. Cryptome INSCOM DVD. Cryptome offers with the Cryptome DVD an INSCOM DVD of about 18,000 pages of counter-intelligence dossiers declassified by the US Army Information and Security Command, dating from 1945 to 1985. No additional contribution required -- $25 for both. The DVDs will be sent anywhere worldwide without extra cost. |
26 September 2006
[Federal Register: September 26, 2006 (Volume 71, Number 186)]
[Notices]
[Page 56159-56162]
From the Federal Register Online via GPO Access [wais.access.gpo.gov]
[DOCID:fr26se06-87]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Notice of Listing of Grants for Research Projects
AGENCY: National Institutes of Health, Department of Health and Human
Services.
ACTION: Notice.
-----------------------------------------------------------------------
[[Page 56160]]
SUMMARY: Section 52.1(b) of the regulations governing grants for
research projects, codified at 42 CFR part 52, authorizes the Secretary
of Health and Human Services to publish periodically a list of all of
the research project grant programs to which the research project grant
regulations apply. This Notice provides the most recent list of the
programs covered by the regulations and supersedes the prior Notice
published on November 25, 2003 (68 FR 66114-66117).
DATES: Effective Date: September 26, 2006.
FOR FURTHER INFORMATION CONTACT: Jerry Moore, NIH Regulations Officer,
Office of Management Assessment, 6011 Executive Boulevard, Room 601,
MSC 7669, Rockville, MD 20892, telephone 301-496-4607 (not a toll-free
number), fax 301-402-0169, e-mail jm40z@nih.gov.
SUPPLEMENTARY INFORMATION: The National Institutes of Health (NIH)
published a final rule in the Federal Register on October 24, 1996 (61
FR 55102-55106), amending the regulations at 42 CFR part 52, Grants for
Research Projects, which govern Public Health Service (PHS) research
project grants. We amended the regulations to apply to all research
project grant programs administered by PHS and its components,
including the programs administered by NIH, except for grants for
health services research, demonstrations, and evaluation projects
administered by the Agency for Healthcare Research and Quality (AHRQ),
to make it unnecessary to include a long list of programs in the
regulations or to go through the lengthy process of amending the
regulations each time a new program is established. At that time, we
provided in the preamble a listing of the applicable programs and
indicated that we would publish periodically a list of the research
project grant programs to which the regulations apply, and that the
applicability of the regulations to new programs would be announced as
PHS components initiated new programs.
Subsequently, we published the Notice entitled, ``Notice of Listing
of Grants for Research Projects,'' in the Federal Register on November
25, 2003. In the Notice we provided an updated list of programs to
which the regulations at part 52 apply that reflected the addition of
new authorities in sections 317J, 317K, 317L, 330E, 399M, 399N, 409E,
434A, 445I, 447B, and 1261 of the Public Health Service Act (PHS Act),
as amended.
We are now publishing a further updated list that reflects the
addition of the new authority in subsections (a) and (f) of section
485D of the PHS Act, as amended, concerning research in complementary
and alternative medicine. Specifically, the authority in subsection (a)
concerns the conduct and support of basic and applied research
(including both intramural and extramural research), research training,
and dissemination of health information with respect to identifying,
investigating, and validating complementary and alternative treatment,
diagnostic and prevention modalities, and disciplines and systems of
complementary and alternative medicine. Subsection (f) concerns the
conduct and support of high quality, rigorous scientific reviewing of
complementary and alternative medicine modalities, including outcomes
research and investigations, epidemiological studies, health services
research, basic sciences research, clinical trials, and other
appropriate research and investigational activities.
The regulations codified at 42 CFR part 52 apply to all PHS
research project grant programs except for grants for health services
research, demonstrations, and evaluation projects administered by the
AHRQ. Specifically, the research project grant authorities to which the
Grants for Research Projects regulations apply include:
(1) Research into the cause, diagnosis, treatment, control, or
prevention of the physical or mental diseases, injuries, or impairments
to human life, as authorized by sections 301, 302, and related
provisions of the PHS Act (42 U.S.C. 241, 242);
(2) Research into the prevention and control of childhood lead
poisoning, as authorized under section 301 of the PHS Act (42 U.S.C.
241);
(3) Epidemiologic studies and State-based research capacity
building projects for the prevention of primary and secondary
disabilities, as authorized under section 301 of the PHS Act (42 U.S.C.
241);
(4) Ecological and epidemiologic research studies in Lyme disease,
including disease surveillance, development and evaluation of
prevention and control studies, and development of improved diagnostic
tests, as authorized under section 301 of the PHS Act (42 U.S.C. 241);
(5) Research for the development of knowledge and approaches to the
epidemiology, eitology, diagnosis, treatment, control, and prevention
of narcotic addiction and intravenous (IV)-related AIDS and drug abuse,
as authorized under sections 301 and 302 of the PHS Act (42 U.S.C. 241,
242);
(6) Investigations to identify strategies for prevention of
childhood deaths from diarrhea, as authorized under sections 301 and
317(k) of the PHS Act (42 U.S.C. 241, 247b(k));
(7) HIV/AIDS surveillance, HIV serosurveillance surveys and
studies, and epidemiologic research studies of AIDS and HIV infection,
as authorized under sections 301 and 317(k) of the PHS Act (42 U.S.C.
241, 247b(k));
(8) Surveillance and epidemiologic studies for the prevention of
infectious diseases and injuries in children in child day care
settings, as authorized under sections 301, 317(k), and 391 of the PHS
Act (42 U.S.C. 241, 247b(k)(3), 280(b));
(9) Research into prevention and control of tuberculosis,
especially research concerning strains of tuberculosis resistant to
drugs and research concerning cases of tuberculosis that affect certain
populations, as authorized by section 317E of the PHS Act (42 U.S.C.
247b-6);
(10) Research with respect to education and training for health
professionals and the general public relating to the effects of folic
acid in preventing birth defects, as authorized by section 317J of the
PHS Act (42 U.S.C. 247b-11);
(11) Research relating to risk factors, prevention strategies, and
the roles of the family, health care providers, and the community in
safe motherhood, as authorized by section 317K of the PHS Act, as
amended by section 901 of Public Law 106-310 (42 U.S.C. 424b-12);
(12) Epidemiological research on the prevention of prenatal and
postnatal smoking, alcohol, and illegal drug use, as authorized by
section 317L of the PHS Act, as amended by section 911 of Public Law
106-310 (42 U.S.C. 247b-13);
(13) Research relating to intervention strategies to improve the
lives of persons with epilepsy, particularly children, as authorized by
section 330E of the PHS Act, as amended by section 801 of Public Law
106-310 (42 U.S.C. 254c-5);
(14) Injury prevention and control research, as authorized by
section 391 of the PHS Act (42 U.S.C. 280b);
(15) Research relating to the efficacy of new screening techniques
and technology, including clinical studies of screening methods and
studies on the efficacy of new interventions regarding hearing loss in
infants, as authorized by section 399M of the PHS Act, as
[[Page 56161]]
amended by section 702 of Public Law 106-310 (42 U.S.C. 280g-1);
(16) Research relating to improving the outcomes among children
with childhood cancers and resultant secondary conditions, as
authorized by section 399N of the PHS Act, as amended by section 1101
of Public Law 106-310 (42 U.S.C. 280g-2);
(17) Research on osteoporosis, Paget's disease, and related bone
disorders, as authorized by section 409A of the PHS Act (42 U.S.C.
284e);
(18) Research relating to autoimmune diseases, as authorized by
section 409E of the PHS Act, as amended by section 1901 of Public Law
106-310 (42 U.S.C. 284i);
(19) Long-term epidemiology studies relating to type 1 or juvenile
diabetes, as authorized by section 434A of the PHS Act, as amended by
section 402 of Public Law 106-310 (42 U.S.C. 285c-9);
(20) Biomedical research in areas relating to Alzheimer's disease
and related dementias, as authorized by section 445B of the PHS Act (42
U.S.C. 285e-4);
(21) Clinical research and training to enhance and promote the
translation of new scientific knowledge into clinical practice related
to the diagnosis, care, and treatment of individuals with Alzheimer's
disease, as authorized by section 445I of the PHS Act (42 U.S.C. 285e-
10a);
(22) Clinical research and training to enhance and promote the
translation of new scientific knowledge into clinical practice related
to the diagnosis, care, and treatment of individuals with sexually
transmitted diseases, as authorized by section 447B of the PHS Act, as
amended by section 901 of Public Law 106-505 (42 U.S.C. 285f-3);
(23) Research relating to medical rehabilitation, as authorized by
section 452 of the PHS Act (42 U.S.C. 285g-4);
(24) Research on clinical and health services on eye care and
diabetes, as authorized by section 456 of the PHS Act (42 U.S.C. 285i-
1);
(25) Research on multiple sclerosis, especially research on the
effects of genetics and hormonal changes on the progress of the
disease, as authorized by section 460 of the PHS Act (42 U.S.C. 285j-
3);
(26) Research on the social, behavioral, and biomedical etiology,
the mental and physical health consequences, and the social and
economic consequences of alcohol abuse and alcoholism, as authorized by
464H of the PHS Act (42 U.S.C. 285n);
(27) Health services research activities with respect to the
prevention of alcohol abuse and treatment of alcoholism, as authorized
by section 464H of the PHS Act (42 U.S.C. 285n) and as defined in
section 409 of the PHS Act (42 U.S.C. 284d);
(28) Research under the Medication Development Program to encourage
and promote the development and use of medications to treat drug
addiction; and to collect, analyze, and disseminate data, as authorized
by section 464P of the PHS Act (42 U.S.C. 285o-4);
(29) Research on health-related educational technologies, on
medical library science and related activities, and for the development
or dissemination of new knowledge, techniques, systems, and equipment
for processing, storing, retrieving, and distributing information
pertaining to health sciences, as authorized by section 473 of the PHS
Act (42 U.S.C. 286b-4);
(30) Research with respect to identifying, investigating, and
validating complementary and alternative treatment, diagnostic and
prevention modalities, disciplines and systems of complementary and
alternative medicine, as authorized by section 485D (a) and (f) of the
PHS Act, as amended (42 U.S.C. 287c-21(a), (f));
(31) Research in the biomedical, contraceptive, development,
behavioral and program implementation fields related to family planning
and population, as authorized by section 1004 of the PHS Act (42 U.S.C.
300a-2);
(32) Basic and applied research regarding traumatic brain injury,
including the development, modification, and evaluation of therapies
and programs of rehabilitation toward reaching or restoring normal
capabilities, as authorized by section 1261 of the PHS Act, as amended
by section 1301 of Public Law 106-310 (42 U.S.C. 300d-61);
(33) Research on the causes, consequences, and approaches of coping
with adolescent sexual relations, contraceptive use, pregnancy, and
parenthood, as authorized by section 2008 of the PHS Act (42 U.S.C.
300z-7);
(34) Research relating to the evaluation of drug treatments for
AIDS not approved by the Commissioner of Food and Drugs, as authorized
by section 2314 of the PHS Act (42 U.S.C. 300cc-14);
(35) International research relating to the development and
evaluation of vaccines and treatments for AIDS, as authorized by
section 2315 of the PHS Act (42 U.S.C. 300cc-15);
(36) Long-term research into treatments for AIDS, as authorized by
section 2320 of the PHS Act (42 U.S.C. 300cc-20);
(37) Research relating to AIDS conducted outside the United States
by qualified foreign professionals and collaborative research involving
American and foreign participants, as authorized by section 2354 of the
PHS Act (42 U.S.C. 300cc-41);
(38) Basic research to identify, characterize, and quantify risks
to human health from air pollutants, as authorized by section 103 of
the Clean Air Act, as amended (42 U.S.C. 7403);
(39) Electronic product radiation control research programs
designed to protect the public health and safety from electronic
product radiation, as authorized by section 532 of the Federal Food,
Drug, and Cosmetic Act, as amended (21 U.S.C. 360ii);
(40) Research into areas where a microgravity environment may
contribute to significant progress in the understanding and treatment
of diseases and other medical conditions, as authorized by section 603
of the National Aeronautics and Space Administration Authorization Act,
Fiscal Year 1993 (42 U.S.C. 2487b);
(41) Support for radiation studies and research, as authorized
under section 301 of the PHS Act (42 U.S.C. 241) and by section 20(a)
of the Occupational Safety and Health Act of 1970 (29 U.S.C. 669(a));
(42) Research on occupational safety and health problems in
industry, as authorized by section 20(a) of the Occupational Safety and
Health Act of 1970 (29 U.S.C. 669(a)) and section 501 of the Federal
Coal Mine Health and Safety Act of 1969 (30 U.S.C. 951); and
(43) Research to stimulate health-related technological innovation
especially through the use of small business, minority, and
disadvantaged firms and increased private sector commercialization of
innovations derived from Federal research and development, as
authorized under section 301 of the PHS Act (42 U.S.C. 241), in
accordance with the procedures prescribed pursuant to section 2[9] of
the Small Business Innovation Development Act of 1982, as amended (15
U.S.C. 638).
The Catalog of Federal Domestic Assistance (CFDA) numbered
programs affected by title 42 of the Code of Federal regulations,
part 52, are:
93.113--Biological Response to Environmental Health Hazards
93.114--Applied Toxicological Research and Testing
93.115--Biometry and Risk Estimation--Health Risks from
Environmental Exposures
93.118--Acquired Immunodeficiency Syndrome (AIDS) Activity
93.121--Oral Diseases and Disorders Research
[[Page 56162]]
93.135--Centers for Research and Demonstration for Health Promotion
and Disease Prevention
93.136--Injury Prevention and Control Research and State and
Community Based Programs
93.172--Human Genome Research
93.173--Research Related to Deafness and Communication Disorders
93.184--Disabilities Prevention
93.213--Research and Training in Complementary and Alternative
Medicine
93.242--Mental Health Research Grants
93.262--Occupational Safety and Health Program
93.271--Alcohol Research Career Development Awards for Scientists
and Clinicians
93.273--Alcohol Research Programs
93.279--Drug Abuse and Addiction Research Programs
93.281--Mental Health Research Career/Scientist Development Awards
93.283--Centers for Disease Control and Prevention--Investigations
and Technical Assistance
93.361--Nursing Research
93.389--National Center for Research Resources
93.390--Academic Research Enhancement Award
93.393--Cancer Cause and Prevention Research
93.394--Cancer Detection and Diagnosis Research
93.395--Cancer Treatment Research
93.396--Cancer Biology Research
93.821--Biophysics and Physiological Sciences Research
93.837--Heart and Vascular Diseases Research
93.838--Lung Diseases Research
93.839--Blood Diseases and Resources Research
93.846--Arthritis, Musculoskeletal and Skin Diseases Research
93.847--Diabetes, Endocrinology and Metabolic Research
93.848--Digestive Diseases and Nutrition Research
93.849--Kidney Diseases, Urology and Hematology Research
93.853--Clinical Research Related to Neurological Disorders
93.855--Allergy, Immunology, and Transplantation Research
93.856--Microbiology and Infectious Diseases Research
93.859--Biomedical Research and Research Training
93.865--Child Health and Human Development Extramural Research
93.866--Aging Research
93.867--Vision Research
93.879--Medical Library Assistance
93.941--HIV Demonstration, Research, Public and Professional
Education Projects
93.942--Research, Treatment and Education Programs on Lyme Disease
in the United States
93.943--Epidemiologic Research Studies of Acquired Immunodeficiency
Syndrome (AIDS) and Human Immunodeficiency Virus (HIV) Infection in
Selected Population Groups
93.947--Tuberculosis Demonstration, Research, Public and
Professional Education
Dated: September 19, 2006.
Elias A. Zerhouni,
Director, National Institutes of Health.
Approved: September 19, 2006.
Michael O. Leavitt,
Secretary.
[FR Doc. E6-15729 Filed 9-25-06; 8:45 am]
BILLING CODE 4140-01-P